Research focus: ‘Health not height’ – Trial results for a targeted treatment for children with achondroplasia
Professor Ravi Savarirayan talks through the recently published results in The New England Journal of Medicine for the C-type natriuretic peptide analogue vosiritide in children with achondroplasia.
Growth hormone prescription differences highlighted for USA vs Europe
Data from two large observational studies show that children treated in the USA receive a higher dose of the commercial growth hormone somatropin and are taller, older, and more likely to be boys than girls relative to those treated in Europe.
C-type natriuretic peptide analogue increases growth velocity in children with achondroplasia
Daily treatment with subcutaneous vosoritide leads to a sustained increase in annualised growth velocity, with generally mild side effects, in children with achondroplasia, show data published in The New England Journal of Medicine.
Expert reviews: Dr Sasha Howard
Delayed puberty is common in the developed world, affecting over 2% of adolescents, and is associated with adverse health outcomes including short stature, reduced bone mineral density and compromised psychosocial health.
IMAGE 2019
This year the Insight for MAnaging Growth for Endocrine nurses (IMAGE) conference was held on 10-11th October 2019 at the Radison Blu Hotel, Bordeaux, France, The aims of the symposium were to provi [...]
GH therapy improves short-term emotional and social life quality for short stature children
Children with short stature show marked improvements in their emotional and social quality of life during their first year of treatment with growth hormone, study findings suggest.
Early oestrogen initiation in Turner syndrome boosts adulthood bone health
A probable underlying genetic cause may be found for the majority of children with severe familial short stature, with mutations in growth plate genes accounting for most of these, research shows.
Growth plate gene mutations may underlie many severe familial short stature cases
A probable underlying genetic cause may be found for the majority of children with severe familial short stature, with mutations in growth plate genes accounting for most of these, research shows.
Case study: A girl aged 15 is referred to an Endocrine Clinic for short stature and delayed puberty
A girl aged 15 years and 2 months is referred to the Endocrine Clinic for short stature and delayed puberty.
GH therapy improves short-term emotional and social life quality for short stature children
Children with short stature show marked improvements in their emotional and social quality of life during their first year of treatment with growth hormone, study findings suggest.
